Status:
UNKNOWN
Impact of a Fourth Hexavalent Vaccine After Hematopoietic Stem Cell Transplantation
Lead Sponsor:
University Hospital, Grenoble
Collaborating Sponsors:
Centre Hospitalier Universitaire de Nice
University Hospital, Clermont-Ferrand
Conditions:
Haemopoietic Stem Cell Transplantation
Allograft
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
It is recommended for patients who underwent an hematopoietic stem cell transplantation to receive 6 months after the graft 3 injections of hexavalent vaccine (diphteria-tetanus- poliomyelitis-pertuss...
Detailed Description
It is recommended for patients who underwent an hematopoietic stem cell transplantation to receive, 6 months after the graft, 3 injections of hexavalent vaccine (diphteria-tetanus- poliomyelitis-pertu...
Eligibility Criteria
Inclusion
- having received an HSTC 6 months before (not more than 2 years)
- not receiving immunosuppressive therapy at inclusion
Exclusion
- having received an HSTC 6 months more than 2 years before
- receiving immunosuppressive therapy at inclusion
Key Trial Info
Start Date :
May 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03402776
Start Date
May 1 2018
End Date
May 1 2021
Last Update
June 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Grenoble, France, 38000